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Abstract 
Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with a very poor 5-year survival 
rate. Alpha-enolase is a glycolytic enzyme that also acts as a surface plasminogen receptor. 
We find that it is over-expressed in PDAC and present on the cell surface of PDAC cell lines. 
The clinical correlation of its expression with tumor status has been reported for lung and 
hepatocellular carcinoma. We have previously demonstrated that sera from PDAC patients 
contain IgG autoantibodies to α-enolase. The present work was intended to assess the ability 
of α-enolase to induce antigen-specific T cell responses. We show that α-enolase-pulsed 
dendritic cells (DC) specifically stimulate healthy autologous T cells to proliferate, secrete 
IFN-γ and lyse PDAC cells but not normal cells. In vivo, α-enolase-specific T cells inhibited 
the growth of PDAC cells in immunodeficient mice. In 8 out of 12 PDAC patients with 
circulating IgG to α-enolase, the existence of α-enolase-specific T cells was also demonstrated. 
Taken as a whole, these results indicate that α-enolase elicits a PDAC-specific, integrated 
humoral and cellular response. It is thus a promising and clinically relevant molecular target 
candidate for immunotherapeutic approaches as new adjuvants to conventional treatments in 
pancreatic cancer. 
 3
Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related deaths in 
Western countries. Despite aggressive surgical and medical management, the mean life expectancy 
is approximately 15-18 months for patients with local and regional disease, and only 3-6 months for 
those with metastatic disease 1. Most patients with advanced disease cannot be operated and 
pancreatic tumor cells are often resistant to chemotherapy and radiation therapy. 
The discovery of human TAA has identified genes relevant in cancer progression and 
recognized by the host immune system 2. Despite the results in animal models, most clinical trials 
with antigen-specific vaccines have so far failed to elicit profound tumor rejection responses. Many 
vaccines induce an albeit weak humoral and cytolytic immune response, whereas a clinically 
evident anti-tumor response is rarely achieved 3. The “elimination phase” of cancer 
immunosurveillance is, of course, not always successful, and tumors with reduced immunogenicity 
or with gained suppression functions are thought to emerge from the immune selection pressure and 
ultimately kill the host 4, 5. In a spontaneous model of in situ PDAC in immune-competent animals, 
indeed, this phase was nearly nonexistent 6. Thus, the failure of immunosurveillance may be an 
early event during PDAC cancerogenesis. In humans, indeed, PDAC is an essentially uniformly 
fatal disease and, although immunotherapy holds promise as a novel strategy in its management 1, 
more efficacious means are urgently needed. Recent data suggest that immunomodulating doses of 
cyclophosphamide given before immunotherapy enhance treatment-induced anti-tumor immune 
responses 7-9, even in the treatment of very aggressive tumors such as those of the pancreas 10. In 
this light, cancer vaccines could be employed in pancreatic cancer as adjuvants to conventional 
treatments and in the management of minimal residual disease following resection of the primary 
cancer. 
In PDAC, only four antigens, namely MUC-1, K-ras, coactosin-like protein, and mesothelin 
induce specific responses by both CD4 and CD8 T cells 10-13. MUC-1 and K-ras also elicit a 
humoral response and have been used in phase I and I/II clinical trials 11, 14. Anti-mesothelin agents, 
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namely recombinant immunotoxin, the chimeric anti-mesothelin mAb and the Listeria 
monocytogenes-mesothelin vaccine are used in clinical practice or about to enter in clinical trials 15. 
Selection of an appropriate TAA is crucial for the design of vaccines and an essential prerequisite 
for induction of a strong immune response. The limited number of PDAC-associated antigens that 
can be candidates for vaccines, and the persistent lack of effectiveness of vaccine trials have 
prompted our search for new TAA. 
SERological Proteome Analysis (SERPA) 16, 17 with PDAC cells as bait to screen IgG in sera 
from PDAC patients has shown that they, but not healthy donors or non-PDAC-related tumor 
patients, display a high frequency of circulating IgG to α-enolase 18. Its ability to induce both CD4 
and CD8-mediated responses in healthy donors and PDAC patients, and T-cell-mediated inhibition 
of PDAC cell growth in nu/nu mice have been evaluated. 
As our results demonstrated that α-enolase elicits efficient cellular responses to PDAC cells 
both in vivo and in vitro, and that PDAC patients expressing circulating IgG to α-enolase display a 
T cell response to it, we propose α-enolase as a novel molecular target for active and passive 
immunotherapies in PDAC. 
 5
Material and methods 
Cells and Tumor Cell Lines. 
The human PDAC cell lines CF-PAC-1 (HLA-A2+, ECACC Ref. No: 91112501), Mia-Pa-Ca-
2 (HLA-A24+, ECACC Ref. No: 85062806), PANC-1 (HLA-A2+, ECACC ref. No: 87092802), 
PaCa44 and K562 cells were cultured in DMEM or RPMI 1640 supplemented with 20 mM 
glutamine, 10% certified FCS (GIBCO, Invitrogen, San Giuliano Milanese, Milan, Italy), and 
Gentamycin (40 µg/ml; Shering-Plough, Milan, Italy). All the in vitro cultures were performed at 
37°C in a humidified 5% CO2 atmosphere. Peripheral blood mononuclear cells (PBMC), T cells and 
dendritic cells (DC) were derived from the peripheral blood of healthy donors from the Blood Bank 
and cancer patients under an Institutional Review Board-approved protocol and with informed 
consent. Healthy donor whole blood was assayed for HLA-A2+ expression by flow cytometry with 
fluorescein thio-isocyanate (FITC)-conjugated mouse anti-human HLA-A2 mAb (BD Biosciences, 
Milan, Italy). 
 
Human keratinocytes. 
Due to the unavailability of normal pancreatic cells that matched with HLA class I of T cells, 
we used normal keratinocytes HLA-A2+ as control in cytotoxic assays. Human split thickness skin 
grafts (0.4 mm thick) harvested from informed consent patients undergoing routine reconstructive 
plastic surgery for various disorders pathologies at the Burn Centre of Turin were mostly taken 
from the breast and a few from the thigh and abdomen. Grafts were put into sterile boxes in an 
appropriate medium, namely RPMI 1640 supplemented with penicillyn-streptomycine (240 µg/ml 
and 200 µg/ml; both from Sigma, Milan, Italy), incubated at 4°C overnight and processed the day 
after. 
Skin keratinocytes were cultivated on a lethally irradiated feeder layer of 3T3-J2 cells, as described 
previously 19. In brief, samples were incubated with dispase at 37°C for 3-4 hours. After epidermal 
separation from the dermal sheet, only the epidermal samples were treated with trypsin (0.05% 
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trypsin and 0.01% EDTA; Sigma). Cells were plated (1.5 x 104/cm2) on lethally irradiated (3000 
rads of X-radiation) 3T3-J2 cells (2.4 x 104/cm2) and cultured in 5% CO2 and humidified 
atmosphere in DMEM containing FCS (10%), insulin (5 mg/ml), hydrocortisone (0.4 mg/ml), 
cholera toxin (0.1 nM), triiodothyronine (2 nM), glutamine (4 mM), and penicillin streptomycin (50 
IU/ml) (all from Sigma). Epidermal growth factor (10 ng/ml, from PeproTech Inc., Rocky Hill, NJ) 
was added 3 days after plating. The culture medium was changed every 2-3 days. Undifferentiated 
keratinocytes from subconfluent cultures 20, 21 from different donors were stained with FITC-
conjugated mouse anti-human HLA-A2 mAb to freeze and store only those HLA-A2+. 
 
Differential expression of α-enolase in normal and PDAC tissues: 
i) Microarray analysis. 
RNA was obtained from 3 chronic pancreatitis (CP), 3 PDAC primary tumors and their 
adjacent normal pancreas (NP) from the surgery Dept. of University of Verona, 8 PDAC xenografts 
and one PDAC cell line (PaCa44). Snap-frozen surgical samples were ground on dry ice with a 
mortar and pestle, suspended in RNeasy Lysis buffer and total RNA was isolated using the RNeasy 
Mini Kit (Qiagen, Hilden, Germany). Total RNA was checked for quality using a BioAnalyzer Lab-
on-a-Chip system (Agilent Technologies, Santa Clara, CA). cDNA were synthesized from 12.5 µg 
of total RNA according to the manufacturer's instructions (Affymetrix, Santa Clara, CA). After in 
vitro transcription, labeling and fragmentation, probes were hybridized to the GeneChip HG-U133A 
containing 22,283 probesets, corresponding to about 15,000 genes. The chips were washed in a 
GeneChip Fluidics Station 400 (Affymetrix), and the results were visualized with a Gene Array 
scanner using Affymetrix software. Array data were normalized and summarized using the RMA 
method 22, supplied in the Affy package 
(http://bioconductor.org/packages/2.0/bioc/src/contrib/affy_1.14.0.tar.gz) for the R statistical 
software (http://www.r-project.org). To assess differential expression, the values of intensity, 
normalized with NP, of two probesets (201231_s_at and 217294_s_at), corresponding to ENO1 
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transcripts, and three probesets (204009_s_at, 204010_s_at and 214352_s_at), corresponding to 
Kras transcripts, were averaged and subjected to linear regression analysis. 
 
ii) Western blot analysis. 
Fresh frozen pancreatic tissue from 3 patients with PDAC and paired adjacent NP, obtained 
from the Regina Elena Cancer Institute (Rome, Italy), and 107 of CF-PAC-1, PANC-1 cells and 
keratinocytes were used for one-dimensional WB analysis. Cold lysis buffer containing 50 mM 
TRIS/HCl pH 7,4, 150 mM NaCl, 1% NP40, 1% Triton X-100, 1 mM DTT, 10 µl/ml inhibitory 
cocktail, 1 mM PMSF (all Sigma) and 10 µl/ml nuclease mix (GE Healthcare Bio-Sciences, Milan, 
Italy) was added to a total of 30-50 mg of fresh-frozen tissue, previously homogenised (T18 basic 
UltraTurrax, IKA, Wilmington, NC), or to CF-PAC-1, PANC-1 cells and keratinocytes (107 
cells/ml of cold lysis buffer). After sonication with an ultrasound sonicator (Hielscher UP200S, 
Hielscher Ultrasonics GmbH, Stuttgart, Germany; 3 × 40 s, amplitude 40 %, cycle 0.5), the mix was 
centrifuged (13000 rpm/min, 30 min, 4°C). Twenty µg of protein extract, measured with the 
Bradford assay (Bio-Rad Laboratories, Hercules, CA), were run on a small NuPAGE® Novex® 4-
12% Bis-Tris pre-cast gel (Invitrogen), and transferred to a nitrocellulose membrane (GE 
Healthcare Bio-Sciences). Anti α-enolase (clone 19/12) 23 and HRP-conjugated anti-mouse IgG 
(Santa Cruz, Celbio, Milan, Italy) Abs were used at 1:1000. Immunodetection was accomplished 
with ECL PLUS (GE Healthcare Bio-Sciences). The resulting chemifluorescent signals were 
scanned with “ProXPRESS 2D” (Perkin-Elmer) and recorded in TIFF format. Intensity of reactive 
lines was quantified, linearized on β-tubulin or actin and expressed as arbitrary units (AU) of 
normalized signal intensity. 
 
iii) Immunohistochemical analysis. 
Immunohistochemical analysis on 10 PDAC tissues and 10 paired adjacent NP was performed 
with an anti-α-enolase mAb (1:100; clone 19/12) followed by a horseradish peroxidase (HRP)-
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conjugated goat anti-mouse IgG (Santa Cruz) and DAB detection kit (Ventana Systems, Tucson, 
AZ). Samples were fixed with formalin and paraffin-embedded. Slides were incubated with the 
primary and secondary Ab and developed in a Ventana ES automated stainer. Images were acquired 
on a Leica DM LA upright microscope equipped with a DC300F camera and were analyzed with 
IM 50 software (Leica, Heidelberg, Germany). 
 
iv) Alpha-enolase immunostaining. 
CF-PAC-1 and Mia-Pa-Ca-2 cells were seeded on cover glasses and allowed to adhere 
overnight in complete medium. Glasses were washed twice with 1% BSA-0.01% sodium Azide 
DPBS (all from Sigma) and incubated with the anti-α-enolase mAb (clone 72/1) 23 or an isotype 
control Ig (Dako, Milan, Italy) for 30 min at 4°C. After two washes, glasses were incubated with a 
TexasRed conjugated anti-mouse IgG and then with the lypophilic Hoechst 44332 (all from 
Molecular Probes, Invitrogen,) to stain nuclei. Glasses were mounted on slides with Moviol 
(Sigma) and observed with a Leica TCS SP2 laser scanning confocal microscope driven by Leica 
Confocal Software. The Images were acquired at room temperature (RT) with a 63 X /1.32 N.A. PL 
APO objective at 1024 X 1024 pixel resolution, recorded as TIF files and processed (Adobe 
Photoshop, Mountain View, CA) to subtract background and enhance lower and middle intensity 
fluorescence. 
 
Production of recombinant histidin-tagged α-enolase. 
The enolase coding sequence (aa 10-434) was obtained by restriction cleavage of the full-
length human α-enolase cDNA 24. The 1.35 kb BglII-XhoI fragment was cloned into the bacterial 
expression vector pRSETA (Invitrogen) in frame with a poly-histidine coding sequence. The 
recombinant α-enolase was overexpressed in the E. Coli strain BL21(DE3)/pLysS (Invitrogen) 
upon induction with 1 mM IPTG (Sigma) and purified on Ni2+ affinity column (Invitrogen) 
according to the manufacturer’s instructions with the following modifications. Bacterial cells were 
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harvested from 1 liter culture by centrifugation and pellets were resuspended in 20 ml of native 
binding buffer (NBB, 20 mM Na2PO4 and 500 mM NaCl, pH 7.8) with the addition of lysozyme 
(100 µg/ml) and sarcosyl 0.7%. The suspension was slowly rocked for 15 min at 4°C. The cell 
lysate was sonicated on ice with ten 40-second pulses at high intensity, then centrifuged at 10000 
rpm for 15 min at 4°C to pellet the insoluble fraction, which was resuspended in 10 ml of 
guanidinium lysis buffer (NBB containing 6M Guanidine Hydrochloride), enriched with 10 µl/ml 
proteases inhibitor cocktail, and incubated for 10 min at RT. The lysate was added to the 
equilibrated column (Ni-NTA agarose column, Invitrogen) and incubated for 30 min at 4°C using 
gentle rotation. Two washes with NBB and 2 with Native Wash buffer (NWB; NBB at pH 6.0) 
followed. The elution was performed with 10 ml of elution buffer (NBB pH 6.0 containing 350 mM 
imidazole). The eluted fractions were dialysed in sterile water, then lyophilised and resuspended in 
sterile pyrogen-free PBS. Aliquots were stored at -20°C. The endotoxin level was less than 0.03 
EU/ml in the Limulus Amebocyte Lysate assay (Pyrogent 0.3 plus; BioWittaker Cambrex 
Biosciences by Lonza, Milan, Italy). 
 
Generation and pulsing of DC. 
Human PBMC were isolated from the venous blood of healthy HLA-A2+ donors by Ficoll-
Paque density gradient centrifugation (GE Healthcare Bio-Sciences). Monocytes were enriched 
with a monocyte isolation kit (Miltenyi Biotech, Calderara di Reno, Bologna, Italy). The 
preparations were consistently > 90% CD14+ as determined by FACSCalibur (BD Bioscences). To 
prepare immature DCs, the enriched monocytes were incubated in six-well culture plates (5x106 
cells/3ml/well) in RPMI 1640 medium supplemented with 10% certified FCS and 100 ng/ml of 
GM-CSF and 50 ng/ml of IL-4 (both PeproTech Inc.) for 6 days as previously described 25. 
Immature DCs were resuspended at 1x106 cells/ml and incubated with the recombinant Histidin 
tagged-α-enolase, human albumin (solution 20% of albumin purified from human plasma, Kedrion, 
Wien, Austria), recombinant human albumin (purified by Pichia pastoris; Sigma) or tuberculin 
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purified protein derivative (PPD, Statens Serum Institut) overnight. After 24 h cells were harvested 
for co-cultures with autologous T cells. 
 
In vitro priming of healthy T cells: i) Proliferative response analysis. 
Unpulsed, α-enolase-, human albumin- and PPD-DC were seeded at decreasing concentration 
(104 to 2500) in RPMI-10% certified FCS in 96-well microplates. After thawing autologous PBMC, 
T cells were purified using a nylon wool column (Robbins Scientific Corporation, BioSpace, 
Sunnyvale, CA) or CD4 and CD8 enriched positively with magnetic beads (Miltenyi Biotech) and 
added at 105 cells/well to DC. Nylon wool purified cells are CD3+ > 90%; positively enriched CD4+ 
> 85% and CD8+ > 92% as determined by FACSCalibur. After 5 days, 1 µCi of [methyl-
3H]thymidine (3HTdR, 25 Ci/mmol) (GE Healthcare Bio-Sciences) was added to each well for 18 
h. Cells were collected with a CELLharvester (Packard Instruments, Meriden, CT, USA) in 
UNIfilter plates and 3HTdR uptake was quantitated (TopCount microplates scintillation counter; 
Packard). All tests were performed in triplicate. 
 
ii) IFN-γ Elispot assay. 
Nitrocellulose plates (Millipore, Milan, Italy) were coated with the anti-IFN-γ capture mAb 
(Endogene, by Tema Ricerche, Bologna, Italy) overnight at 4°C. CF-PAC-1 cells or autologous 
DCs previously pulsed with 10 µg/ml of recombinant α-enolase or human albumin overnight were 
mixed with T cells from co-culture with unpulsed DC (referred to as "unstimulated T cells") or α-
enolase-DC ("α-enolase-stimulated T cells") at Stimulator:T cell ratio of 1:10, for 20 h at 37°C. The 
T cells, or purified CD4 and CD8 where indicated, were seeded at 2.5 x 104-105 cells/well. In a few 
experiments, stimulator cells were incubated with anti-HLA class I (clone W6.32) or class II (clone 
AA384 kindly provided by Dr. Ada Funaro, University of Turin) mAb and then added to effector 
cells. The plates were then washed in PBS plus 0.1% of Tween and incubated with a biotin-
conjugated anti-IFN-γ mAb (Endogene) for 2 h at 37°C. After washing, avidin-peroxidase was 
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added to the plate for 30 min. The reaction was developed using AEC substrate (Sigma), and spots 
were quantified with the microplate reader along with a computer-assisted image analysis system 
(AID, Amplifon, Buttigliera, Turin, Italy).  
 
iii) Cytotoxicity assay. 
Target cells were labeled with 50 µCi sodium chromate (Na251CrO4, > 50 Ci/g Cr; Perkin 
Elmer, Milan, Italy) for 60 min at 37°C, washed three times and plated at 103 cells/well in a 96-well 
U-bottom plate with various numbers of purified CD8 effector cells. The plates were briefly 
centrifuged and incubated for 4 h at 37°C. All determinations were done in triplicate. Fifty µl of 
supernatants were harvested on LUMA plates (Packard) and counted on a TopCount microplates 
scintillation counter. Maximum release was obtained by adding 25 µl of Triton X-100 to the labeled 
target cells. Spontaneous release was obtained by incubating the labeled cells in the absence of T 
cells. Percent of specific lysis was calculated from the following formula: % specific lysis = 100 x 
(experimental release - spontaneous release) / (maximum release - spontaneous release). Due to the 
difficulty of Cr uptake by keratinocytes, cytotoxic activity by α-enolase-stimulated T cells was 
evaluated with GranToxiLux kit (OncoImmunin Inc., Gaithersburg, MD, US) by flow cytometry 
following the manufacturer’s instruction. In a few experiments, target cells were incubated with 
anti-HLA class I or class II mAb and then added to effector cells. 
 
In vivo experiments. 
One million CF-PAC-1 cells were injected sub cute in athymic nu/nu mice (Harlan-Nossan, 
San Pietro del Natisone, Italy). Three days later, 3 mice were sacrified to histological analysis of 
tumor takes and the other ones were injected or not intravenously with 107 unstimulated, albumin- 
or α-enolase stimulated T cells from healthy HLA-A2+ donors. Mice were treated with anti-asialo 
GM-1 rabbit serum (0.2 ml/mouse of a 1:20 dilution; Cedarlane, by Celbio, Milan, Italy) 1 day 
before and once a week for four weeks after the tumor challenge to eliminate NK reactivity. 
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Progressively growing masses with a mean diameter of >2 mm were regarded as tumors. Growth 
was monitored twice a week until a tumor exceeded a mean diameter of 15 mm, when mice were 
sacrificed according to accepted animal use protocols. 
 
PDAC patient cellular reactivity to α-enolase. 
18 PDAC patients were divided into those that did or did not displayed IgG to α-enolase 
evaluated by SERPA, performed as previously described 26. Briefly, CF-PAC-1 protein extract was 
separated by 2-DE, blotted onto a nitrocellulose membrane and probed with PDAC serum (4 h, 
1:200 working dilution) or mouse anti-α-enolase mAb (clone 19/12, for 1 h, 1:1000 working 
dilution). Membranes were incubated with HRP-conjugated goat anti-human IgG or HRP-
conjugated goat anti-mouse IgG (both 1 h, 1:2000 working solution, Santa Cruz) and revealed with 
ECL PLUS. The resulting chemifluorescent signals were scanned with “ProXPRESS 2D” 
(PerkinElmer) and recorded in TIFF format. Results were expressed as arbitrary units (AU) 
calculated as the mean of volume intensity of the six α-enolase isoforms. Sera that displayed a more 
than 0.5 AU volume intensity were classified as positive. The AU range of six negative patients was 
from 0.02 to 0.33 (mean 0.2 ± 0.15 SD), whereas the AU range of twelve positive patients was from 
1.34 to 17.0 (mean 9.9 ± 6 SD). 
Two x 105 PBMC/well from PDAC patients were stimulated or not with 10µg/ml recombinant α-
enolase in a 96-well plates. T cell cultures were fed every 3-4 days with 10 U/ml of IL-2 
(PeproTech Inc., by Tebu-bio), and re-stimulated or not with 10µg/ml recombinant α-enolase on 
day 11 for 20 h. PBMC recovered were seeded in Elispot plates, previously coated with anti-IFN-γ 
mAb, and kept in an incubator for a further 20 h. The reaction was developed as previously 
described. 
 
Statistical analysis. 
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Student's t-test (GraphPad Prism 4 Software, Inc., San Diego, CA) was used to evaluate the 
differences in T cell proliferation, IFN-γ secretion (no. of spots), % of specific lysis and in mouse 
tumor diameter at all time points. 
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Results 
Alpha-enolase is over-expressed at both mRNA and protein levels. 
Microarray data generated from pancreatic tissues from 3 paired adjacent PDAC NP, 3 
PDAC, 3 CP, PaCa44 PDAC cell line and 8 PDAC transplanted in immmunosuppressed mice 
(PDAC xenograft) show a significant differential level of α-enolase mRNA expression in tumor 
tissues compared to normal pancreas or CP (Fig. 1a). This inflammatory and not neoplastic lesion is 
histologically characterized by a strong desmoplastic reaction, similar to PDAC 27, while PDAC 
xenografts are a purified source of adenocarcinoma cells in vivo. To assess differential expression, a 
linear regression analysis was performed on logarithmic intensity values as a function of the sample 
class. Compared to NP, the expression of α-enolase was significantly enhanced in PDAC (P < 
0.001), PaCa44 (P < 0.001) and PDAC xenografts (P < 0.001), whereas no difference of expression 
was observed with respect to CP samples (P = 0.419). Of note, the α-enolase levels in PDAC were 
comparable with or higher than those of Kras, an established oncogene mutated in virtually all 
PDAC cases 14.The differential expression of α-enolase was confirmed at protein level by WB and 
immunohistochemistry. Total protein extract from 3 bioptic PDAC and their paired adjacent NP 
was analysed with the mAb to α-enolase, and PDAC displayed higher amounts of α-enolase protein 
compared to NP (Fig. 1b). Furthermore, immunohistochemical analysis of neoplastic and adjacent 
NP lesions of 10 PDAC patients revealed that in the latter, α-enolase expression was restricted to 
medium-small ducts whereas the acinar cells were negative. In contrast, PDAC tissues diffusely 
expressed α-enolase in the cells lining the neoplastic ducts infiltrating the stroma (Fig. 1c). 
Confocal microscopy showed that α-enolase was expressed on the surface of not permeabilized CF-
PAC-1 (upper right panel) and Mia-Pa-Ca-2 (lower right panel) cells. 
 
Alpha-enolase-DC activate a specific proliferative response by T cells. 
To characterize the immunogenic activity of α-enolase, we first assessed its ability to activate 
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T cells. Autologous DC, as professional APC, were pulsed with recombinant α-enolase and co-
cultured with autologous purified T cells from six healthy donors. Compared to unpulsed DC, those 
pulsed with α-enolase induced a significant increase of T cell proliferation in all donors (Fig. 2a). 
This response was dose-dependent and specific, since it was not induced by albumin-DC (Fig. 2b). 
To exclude any reactivity due to the different preparation of recombinant α-enolase and plasma 
purified albumin, we also compared the proliferation induced by plasma and Pichia pastoris 
purified albumin and no significant differences were observed (data not shown). Both purified CD4 
and CD8 T cells from four healthy donors displayed significant proliferation in response to α-
enolase-DC (Fig. 2c). In four independently tested donors, α-enolase always induced proliferation 
from 25 to 50% lower than that induced by the recall Ag PPD, suggesting that the response to α-
enolase is a primary and not a recall response (data not shown). 
 
Alpha-enolase-DC induce specific IFN-γ production by CD4 and CD8 T cells. 
T cells from healthy HLA-A2+ donors were co-cultured with autologous unpulsed or α-
enolase pulsed DC. After 7 days, IFN-γ production was evaluated by Elispot in response to α-
enolase-DC, CF-PAC-1 cells and normal keratinocytes (HLA-A2+). Anti-HLA class I or anti-HLA 
class II mAb were added to determine the dependence of the IFN-γ production on MHC. 
Unstimulated T cells displayed a few spots that were not affected by the presence of anti-HLA class 
I or II mAb (Fig. 3a). By contrast, α-enolase-stimulated T cells displayed a significantly increased 
number of IFN-γ secreting cells in response to either α-enolase-DC or CF-PAC-1, but not to normal  
keratinocytes (Fig. 3a). Both anti-HLA class I and II mAb significantly decreased the number of 
IFN-γ secreting T cells elicited by α-enolase-DC or CF-PAC-1 (Fig. 3a). No IFN-γ secreting cells 
were observed when T cells were primed by DC pulsed with α-enolase pre-absorbed with anti α-
enolase mAb (data not shown). 
Both unstimulated CD4 and CD8 T cells from healthy HLA-A2+ donors did not produce IFN-
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γ when tested against DC pulsed with α-enolase or albumin. In contrast, an increased number of 
IFN-γ spots were observed in both α-enolase stimulated CD4 and CD8 T cells in response to DC 
pulsed with α-enolase but not to DC pulsed with albumin (Fig. 3b). Of note, only α-enolase 
stimulated CD8 T cells were induced to secrete IFN-γ by CF-PAC-1 (Fig. 3b). 
 
Alpha-enolase induces anti-tumor cytotoxic effector T cells. 
HLA-A2+ T cells from healthy donors were co-cultured with unpulsed or α-enolase-DC for 7 
days and their ability to lyse two PDAC cell lines was evaluated in a 4 h Cr release assay. Purified 
CD8 T cells stimulated with α-enolase-DC lysed HLA-A2+ CF-PAC-1, whereas HLA-A24+ Mia-
Pa-Ca-2 or autologous DC were not lysed (Fig. 4a, b, c). The NK-sensitive K562 cell line used as 
negative control of the HLA class I-dependent cytotoxicity was not lysed (Fig. 4d). The ability of 
α-enolase to induce CD8 CTL that lyse CF-PAC-1 cells was confirmed in an additional five HLA 
A2+ healthy donors (Fig. 4e). As a whole, these data clearly indicate that in vitro α-enolase induces 
anti-tumor cytotoxic effector T cells. 
 
Alpha-enolase specific T cells do not kill normal cells. 
In considering α-enolase as a potential target for immunotherapy, we addressed the question 
of whether its expression in normal tissues spares them from α-enolase-specific CTL. The ability of 
α-enolase stimulated CD8 T cells from healthy HLA A2+ donors to lyse HLA matched normal 
human keratinocytes was evaluated by GranToxiLux assay. WB analysis indicated that HLA-A2+ 
CF-PAC-1 and PANC-1 cells express 3-fold more α-enolase than keratinocytes (Fig. 5b). Alpha-
enolase specific CD8 T cells were more efficient in lysing CF-PAC-1 and PANC-1 than 
keratinocytes, suggesting a direct correlation between α-enolase expression and specific-CTL lysis 
(Fig 5a). Anti-HLA class I but not class II mAb incubation completely inhibited lysis and thus 
confirmed the dependence of the cytotoxicity on MHC class I. 
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 Alpha-enolase-specific T cells inhibit the growth of PDAC cells in vivo. 
The efficacy of α-enolase stimulated T cells to inhibit the growth of PDAC cells in vivo was 
also evaluated. Nu/nu mice were injected sub cute with 106 CF-PAC-1 cells and three days later, 
when the tumor was well established, as evaluated by histological analysis (Fig. 6, insert), were 
challenged or not with 107 HLA A2+ unstimulated, albumin or α-enolase-stimulated T cells. Mice 
were treated with anti-asialo GM-1 to eliminate their NK reactivity against CF-PAC-1 cells. In all 
groups CF-PAC-1 cells gave rise to 2 mm diameter tumor masses after 9 days and the i.v. injection 
of unstimulated or albumin stimulated T cells did not affect tumor growth (Fig. 6). A significant 
delay in the growth of CF-PAC-1 cells, indeed, was only evident in mice injected with α-enolase 
stimulated T cells (Fig. 6). 
 
T cell responses against α-enolase correlate with the presence of anti-α-enolase IgG in PDAC 
patients. 
As previous data have indicated that anti-α-enolase IgG are present with high frequency in 
sera from PDAC patients 18, we evaluated whether this humoral response correlates with the ability 
of T cells to secrete IFN-γ in response to α-enolase. PBMC from 12 PDAC patients with and 6 
PDAC patients without IgG to α-enolase were left unstimulated or stimulated with α-enolase, and 
expanded in the presence of IL-2. After 11 days of culture PBMC were tested in a 40 h IFN-γ 
Elispot in the presence or not of α-enolase. With a cut-off of 10 spots/105 cells, eight out of twelve 
patients that displayed IgG reactivity to α-enolase showed a significantly increased number of IFN-
γ secreting cells in response to α-enolase (Fig. 7a): in four patients (#5, #6, #7 and #11) this 
occurred independently of the in vitro expansion (Fig. 7a, left panel); in four (#2, #4, #8 and #12) 
IFN-γ production was observed only after in vitro expansion (Fig. 7a, right panel). None of the six 
patients who did not display IgG reactivity to α-enolase had IFN-γ secreting cells after the primary 
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stimulation (Fig. 7a, lower left panel) or after the in vitro expansion (Fig. 7a, lower right panel), and 
the few spots counted for these patients were much smaller and of lower intensity than those from 
patients with IgG to α-enolase (data not shown). From patients #12 (with) and #18 (without IgG 
reactivity) we purified CD4 and CD8 cells prior to the Elispot assay. IFN-γ secreting cells were 
only present among those from patient #12 and increased after in vitro expansion (Fig. 7b). 
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DISCUSSION 
 
This study demonstrates that α-enolase may be a promising PDAC associated antigen and 
molecular target suitable for therapeutic approaches. We show that it is abundantly and broadly 
expressed in both the cytoplasm and cell surface of PDAC. Its surface expression has been reported 
in myeloid and mammary tumor cell lines 23, 28. Interestingly, microarray data indicated that α-
enolase is not increased in pancreatic tissues from CP, but only in PDAC. This strengthens the 
hypothesis that up-regulation of α-enolase is associated with pancreatic tumorigenesis rather than 
general inflammation. In the hypoxia that occurs in tumor sites, α-enolase expression is up-
regulated by the presence of an Hypoxia Responsive Element (HRE) in its promoter 29-31. In 
addition, α-enolase over-expression has been clinically associated with tumor status for lung and 
hepatocellular carcinoma 32, 33. 
Alpha-enolase induces an antibody response in almost two-third of PDAC patients, but not in 
healthy donors, non-PDAC tumor patients and chronic pancreatitic patients 18. PDAC patients did 
not display signs of autoimmunity, though the presence of anti-α-enolase antibodies has been 
described in patients with autoimmune disorders 23, 34-39. 
It is known that α-enolase expressed at cell surface acts as a plasminogen receptor 28, 40. The 
bound plasminogen is more efficiently activated to plasmin and thus contributes to pathological 
processes such as tumor cell invasion, metastases and inflammatory responses 41. The role of these 
antibody responses remains to be defined in the clinical follow-up. Even so, our data show that a 
clear correlation exists between the presence of antibodies and the ability of PDAC patient T cells 
to respond to α-enolase. Of note, only an in vitro boost with α-enolase was enough to elicit IFN-γ 
production by T cells from patients with anti-α-enolase IgG, whereas no T cells from patients 
without anti-α-enolase IgG, secreted IFN-γ following either primary stimulation or in vitro 
expansion. The induction of an integrated humoral and cellular immune response to TAA has been 
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proved to efficiently drive clinical responses by tumor patients 42, 43. Thus, the spontaneous humoral 
and cellular immune responses elicited by α-enolase in a subset of patients with α-enolase-
expressing PDAC may be an highly favourable characteristic for a vaccine target. 
Our data demonstrate that α-enolase elicits anti-tumor T cell effectors to kill PDAC cells both 
in vitro and an in vivo nu/nu mouse model, where CF-PAC-1 cell growth was delayed by α-enolase 
stimulated T cells injected i.v. after tumor was established. Of note, the CTL response to α-enolase 
spared both autologous DC and normal keratinocytes. Cytotoxicity is dependent on the level of α-
enolase expression, which is much higher in PDAC cells than normal cells such as keratinocytes. It 
will be important to characterize the α-enolase epitopes responsible for T cell reactivity in PDAC to 
improve their recognition and activation. In this respect, studies with C. albicans and C. tropicalis 
have identified cytosolic α-enolase as an immunodominant antigen 44-47, and Sato et al. described a 
single HLA-DR-restricted peptide of human α-enolase identified in squamous cell carcinoma that 
elicited cytotoxic activity by CD4 T cells 48. Our data suggest that α-enolase is recognized in the 
context of HLA-A2 allele. 
Taken as a whole, these data show that a T and B cell integrated anti-tumor response against 
α-enolase can be induced. It is thus a promising candidate for new immunotherapeutic approaches 
to be associate with conventional approaches in the treatment of PDAC. Recent data indicated that 
the combined chemo-immunotherapy may constitute a new strategy with which to control tumor 
progression 49. The immune system, indeed, could be elicited in two ways by conventional 
therapies. Some therapeutic programmes elicit specific cellular responses that render tumor-cell 
death immunogenic 50. Other drugs may have side-effects that stimulate the immune system through 
different mechanisms. Moreover, vaccination against cancer-specific antigens may sensitize a tumor 
to subsequent chemotherapy 49. Thus, it may be possible to design adjuvant therapies to elicit anti-
α-enolase responses to treat surgically resected patients to avoid recurrent disease, or for 
untreatable patients to prolong overall survival. 
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Figure Legends 
 
Figure 1. Alpha-enolase is differentially expressed in PDAC compared to normal pancreatic tissues. 
(a) Differential expression of the ENO1 (●) and Kras (  ) mRNA according to microarray data. The 
data are shown as base-two logarithm ratio of intensity values compared with median intensity of NP. 
The p-values are calculated by linear regression analysis: NP vs CP 0.419; NP vs PDAC <0.001; NP vs 
PaCa44 <0.001; NP vs PDAC xenograft <0.001. (b) Mean of normalized intensity relative to α-enolase 
expression evaluated by WB from 3 PDAC biopsies and 3 adjacent NP. In the insert (upper) one of 
three representative WB with anti-α enolase mAb from total protein extract from NP and PDAC tissues 
is shown. Anti-β-tubulin mAb was used as internal control (insert, lower). (c) Immunohistochemical 
analysis of formalin-fixed and paraffin imbedded sections of NP (left panel) and PDAC tissues (right 
panel) with anti-α-enolase mAb. Stained sections were counterstained with hematoxylin. All images 
were taken with a x 60 objective. (d) CF-PAC-1 and Mia-Pa-Ca-2 cells were seeded on cover glasses, 
fixed and stained with an isotype control Ig (left panels) or the anti-α enolase mAb (red, right panels). 
Nuclei are stained in blue by Hoechst 43332. 
 
Figure 2. Alpha-enolase elicits a proliferative response by both CD4 and CD8 T cells. 
(a) Proliferative response to α-enolase-DC by T cells from 6 healthy donors independently tested. All 
three T:DC ratios are shown. White bars correspond to T cells cultured with unpulsed DC and black 
bars to T cells cultured with α-enolase-pulsed DC. The proliferative response was quantitated as 
3HTdR uptake. (b) T cells were cultured with unpulsed (○), three different concentrations of α-enolase 
(black symbols) or human albumin (□) pulsed-DC. A mean of three donors independently tested is 
shown. *P < 0.05, values from T cells cultured with α-enolase pulsed DC compared to T cells cultured 
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with unpulsed DC. (C) Magnetic beads-positively enriched CD4 and CD8 T cells from 4 healthy 
donors were cultured with autologous unpulsed (white bars) or pulsed with α-enolase (black bars) DC. 
Results obtained at 20:1 T/DC ratio (10000 DC/well) are shown. 
 
Figure 3. Alpha-enolase induces IFN-γ secretion by T cells. (a) DC unpulsed or pulsed with α-enolase 
were cultured with autologous T cells (called unstimulated T cells, white bars, and α-enolase 
stimulated T cells, black bars, respectively) for 1 week. Recovered T cells were further stimulated in 
Elispot plates for 20 h in the presence of α-enolase-DC (left panel), CF-PAC-1 (middle panel) and 
normal human keratinocytes (hKER) (right panel) previously incubated or not with anti-HLA class I or 
II mAb. For all stimulation conditions the background (T cells stimulated with medium alone or 
unpulsed DC) is shown (grey bars). One of three independent experiments is shown. (b) CD4 (left 
panel) and CD8 (right panel) T cells respectively were enriched with magnetic beads from T cells 
recovered from co-cultures with unpulsed DC or with α-enolase DC, and stimulated with α-enolase or 
albumin pulsed DC and CF-PAC-1 in Elispot plate. One of three independent experiments is shown. 
 
Figure 4. Alpha-enolase induces cytotoxic activity by purified CD8 T cells. Cytotoxic activity by CD8 
purified T cells from ustimulated T cells (white symbols) and α-enolase-stimulated T cells (black 
symbols) was evaluated against HLA-matched CF-PAC-1 (a), not matched Mia-Pa-Ca-2 (b) 
autologous DC (c) and K562 (d) target cells in a 4 h 51Cr release assay. One of six independent 
experiments is shown. (e) Cytotoxic activity against CF-PAC-1 cells by purified CD8 T cells from 5 
donors independently tested. Each graph correspond to single donor. All conditions were done in 
triplicate wells, thus each value of % of lysis is the mean of 3 values. *P < 0.05, values for % of 
specific lysis by CD8 purified T cells from α-enolase-stimulated T cells compared to that by CD8 
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purified T cells from unstimulated T cells. 
 
Figure 5. Correlation between α-enolase expression and MHC-restricted cytotoxicity. (a) The α-
enolase fold increased expression was reported by assigning a value of 1 to normalized volume 
intensity evaluated from the total protein extract of hKER. Cytotoxic activity by T cells from α-
enolase-stimulated T cells against HLA-matched hKER, CF-PAC-1 and PANC-1 was evaluated by 
flow cytometry. Percentage of specific lysis by α-enolase stimulated T cells was calculated by 
subtracting that by T cells from unstimulated T cells. Anti-HLA class I and II mAb were added to 
target cells before the incubation with the effector cells. * P < 0.05, values for % of specific lysis by α-
enolase-stimulated T cells against PDAC cells compared with that against anti-HLA class I mAb pre-
treated PDAC cells. (b) Alpha-enolase expression analysed in hKER, CF-PAC-1 and PANC-1 cells by 
WB. One of three representative WB with anti-α enolase mAb on total protein extract from human 
keratinocytes, CF-PAC-1 and PANC-1 cells is shown. Anti-actin mAb was used as internal control and 
to normalize volume intensity. 
 
Figure 6. In vivo inhibition of PDAC growth by α-enolase specific T cells. (a) Nu/nu mice were 
injected with CF-PAC-1 cells s.c. and three days later were challenged i.v. in the absence (□) or 
presence of unstimulated (◊), albumin- (○) or α-enolase-stimulated (●) T cells. Tumor growth was 
monitored biweekly. The growth of tumor masses is shown. All nu/nu mice were sacrificed when 
tumor masses reached 15 mm in diameter. **P < 0.05 vs CF-PAC-1 cells alone, plus unstimulated or 
albumin-stimulated T cells; (insert) Hematoxylin staining of formalin-fixed and paraffin imbedded 
sections of CF-PAC-1 cells 3 days after tumor challenge in nu/nu mice. Image was taken with a x 40 
objective. Arrow indicates inguinal lymph node. 
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Figure 7. PDAC patients display an antigen-specific T cell response to α-enolase. (a) PBMC from 
PDAC patients with (upper panels) and without (lower panels) α-enolase specific serum IgG were 
expanded in vitro for 11 days with low doses of IL-2 in the absence (left panels) or presence (right 
panels) of recombinant α-enolase. IFN-γ secreting cells were evaluated after further stimulation with 
recombinant α-enolase in Elispot plates for 40 h. The number of spots in response to α-enolase 
represented in the graph is obtained by subtracting that in the absence of stimuli. (b) CD8 and CD4 T 
cells were purified after 11 days' culture from patients #12 (with) and #18 (without) α-enolase specific 
serum IgG and their ability to secrete IFN-γ in response to α-enolase was assessed in the Elispot assay. 
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